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Adiponectin is assembled into trimer (LMW), hexamer (MMW) and high-molecular-weight (HMW)
multimer in adipocytes. The HMW adiponectin is more metabolically active and closely associated
with peripheral insulin sensitivity. In this study, we reported that berberine, an isoquinoline alka-
loid with insulin-sensitizing effect, inhibits the expression of adiponectin, but promotes the assem-
bly of HMW adiponectin and increases the ratio of HMW to total adiponectin. Berberine activates
AMPK. Knockdown of AMPKa1 abolishes the effect of berberine. Activation of AMPK by AICAR also
increases the level of HMW adiponectin. Our study suggested that activation of AMPK by berberine
promotes adiponectin multimerization.
Structured summary of protein interactions:
Adiponectin physically interacts with Adiponectin by comigration in gel electrophoresis (View Interac-
tion 1, 2)
Adiponectin physically interacts with Adiponectin by cosedimentation through density gradient (View
interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction molecular-weight (HMW) of 18–36 monomers [13–15]. DifferentThe level of adiponectin, the most abundant adipokine present
in human serum, is inversely correlated with obesity and obes-
ity-associated complications [1,2]. Weight loss, caloric restriction,
or thiazolidinedione (TZD) treatment increases adiponectin levels,
and this increase correlates with increased insulin sensitivity
[3–5]. Therefore, adiponectin is a promising candidate for the
development of drugs to treat type 2 diabetes and other obesity-
related metabolic diseases.
It is well established that adiponectin enhances insulin sensitiv-
ity in both skeletal muscle and liver tissues. The effect of adiponec-
tin is mediated by two distinct receptors: AdipoR1 and AdipoR2
[6,7]. The insulin sensitizing effect of adiponectin on liver and mus-
cle is due primarily to its ability to activate AMPK [8,9], an evolu-
tionarily conserved and ubiquitously expressed protein kinase that
acts as a sensor of cellular energy status [10]. Impaired adiponectin
signaling caused by decreased expression of adiponectin or adipo-
nectin receptors leads to insulin resistance [7,11,12].
Adiponectin is secreted from adipocytes into the circulation as
three complexes: trimer (LMW), hexamer (MMW) and the high-chemical Societies. Published by Eadiponectin oligomers possess distinct biological functions on dif-
ferent target tissues. The HMW adiponectin is more metabolically
active and closely associated with peripheral insulin sensitivity
[15,16]. Proportion of the oligomers changes according to meta-
bolic status and disease states. In patients with type 2 diabetes,
the serum levels of HMW adiponectin are selectively decreased
[17]. Impaired multimerization of adiponectin is associated with
reduced level of adiponectin, obesity and insulin resistance
[13,18,19]. The ratio of HMW to total adiponectin shows a strong
correlation with TZD-mediated improvement in insulin sensitivity
[20]. Therefore, oligomerization represents a key mechanism that
regulates the multiple activities of adiponectin [16,21].
The biosynthesis and secretion of adiponectin in adipocytes are
regulated at multiple levels through multiple mechanisms
[16,21,22]. Assembly and secretion of adiponectin oligomers, espe-
cially the HMW adiponectin, is tightly controlled by two ER-resi-
dent chaperone proteins, ERp44 and Ero1-La [23,24]. DsbA-L, a
25 kDa adiponectin-interactive protein, promotes HMW adiponec-
tin assembly and secretion [25,26]. PPARc agonists selectively in-
crease the circulating concentrations of HMW adiponectin
through up-regulation of expression of Ero1-La and DsbA-L
[24,26]. This ﬁnding raises the possibility of targeting the cellular
proteins involved in adiponectin multimerization as a way to in-
crease the serum level of HMW adiponectin.lsevier B.V. All rights reserved.
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Rhizoma coptidis, has a wide range of pharmacological functions,
such as anti-diarrheic, anti-cancer, and anti-inﬂammation [27]. Re-
cent studies have demonstrated beneﬁcial effects of berberine on
improving glucose tolerance and insulin sensitivity [28–32]. These
beneﬁcial effects are related in part to the ability of berberine to
activate AMPK [28,31]. In this study, we investigated the effect of
berberine on adiponectin multimerization in 3T3-L1 adipocytes.
We found that berberine promotes the assembly of HMW adipo-
nectin through activation of AMPK.
2. Materials and methods
2.1. Reagents and antibodies
Berberine, AICAR, 3-isobutyl-1-methylxanthine, dexametha-
sone, insulin, Oil Red O and antibody against b-actin were pur-
chased from Sigma. Antibodies against phospho-AMPK, AMPKa
or AMPKa1 were purchased from Cell Signaling or Upstate
Biotechnology. siRNA oligonucleotide targeting mouse AMPKa1
(the sequence: ACAUAUGCUGCAGGUGGA) was synthesized at
GenePharma (Shanghai, China).
2.2. RNA isolation and real-time PCR
Total RNA was isolated from 3T3-L1 adipocytes and reversed
transcribed as described [33]. Real-time PCR was carried out in
an ABI PRISM 7500 real-time PCR system. The expression levels
of adiponectin, aP2 or PPARc were normalized using b-actin as
an internal control. The primers are:
Adiponectin-Forward: 50-GAACTTGTGCAGGTTGGATGGCAG-30
Adiponectin-Reverse: 50-GGCTATGGGTAGTTGCAGTCAGTT-30
PPARc-Forward: 50-CTGGAATTAGATGACAGTGACTT-30
PPARc-Reverse: 50-CTCATGTCTGTCTCTGTCTTCT-30
aP2-Forward: 50-ACATGATCATCAGCGTAAATGGG-30
aP2-Reverse: 50-TCATAACACATTCCACCACCAGC-30
b-actin-Forward: 50-CACCAGGGTGTGATGGTGGGAAT-30
b-actin-Reverse: 50-GGTCTTTACGGATGTCAACGTCACA-30
2.3. Cell culture, cell differentiation and treatment
3T3-L1 preadipocytes (ATCC) were grown in DMEM (Invitrogen)
supplemented with 10% FBS (Hyclone) at 37 C in 5% CO2 and dif-
ferentiated into mature adipocytes by a conventional method [13].
To examine the effect of berberine on differentiation, 3T3-L1 pre-
adipocytes were induced to differentiate in the presence of berber-
ine. At day 8 post-differentiation, cells were stained with Oil Red O.
3T3-L1 adipocytes were incubated in serum-free medium contain-
ing 0.05% BSA for 16 h before berberine or AICAR was added. 3T3-
L1 adipocytes were transfected with mouse AMPKa1 siRNA for
48 h followed by treatment with berberine.
2.4. Cloning and antibody production
Full-lengthadiponectin cDNAandDsbA-LcDNAwereobtainedby
RT-PCR and cloned into pCR3.1. The sequence was veriﬁed by DNA
sequencing. Antibodies against the globular domain of adiponectin
or the N-terminal peptide of adiponectin were generated as de-
scribed previously [13]. Rabbit polyclonal antibody against DsbA-L
was generated using GST-DsbA-L puriﬁed from Escherichia coli.
2.5. SDS–PAGE and western blot analysis
Cell lysates of 3T3-L1 adipocytes were subjected to 2–15%
gradient gel electrophoresis under non-reducing and non-heat-denaturing conditions as described [13]. Adiponectin oligo-
mers were detected using anti-globular domain antibodies. To
examine the total amount of adiponectin, the samples were pre-
pared as described [13]. Adiponectin monomer was detected using
antibody raised against the N-terminal peptide. AMPK was de-
tected using antibodies speciﬁc for phospho-AMPK or AMPKa.
The relative abundance of adiponectin oligomers or monomer
was quantiﬁcated by analyzing the western blots using the NIH Im-
ageJ software. All experiments were performed at least three times
and representative results were presented.2.6. Velocity sedimentation for separation of adiponectin oligomers
Fractionation of adiponectin oligomers was carried out by sep-
aration on sucrose gradients as described previously [15]. Gradient
fractions were analyzed by western blotting of equal volumes after
reduction and denaturation.3. Results
3.1. Berberine promotes adiponectin multimerization during
differentiation
To examine the effect of berberine on differentiation, 3T3-L1
preadipocytes were induced to differentiate in the presence of dif-
ferent concentrations of berberine. A striking reduction in lipid
contents was seen in berberine-treated cells; fewer and smaller li-
pid droplets were seen in cells treated with 4 lM berberine for
8 days (Fig. 1A). This is consistent with early reports that berberine
inhibits differentiation of 3T3-L1 preadipocytes [31,34]. Berberine
treatment resulted in a substantial reduction in the mRNA levels
of adiponectin, aP2 and PPARc (Fig. 1B). PPARc is an important
transcriptional regulator of adipogenesis [35]. These results dem-
onstrated that berberine inhibits differentiation of 3T3-L1 preadi-
pocytes and suppresses the transcription of adiponectin during
differentiation.
To investigate the effect of berberine on adiponectin multimer-
ization during differentiation, we examined the level of adiponec-
tin oligomers on 2–15% gradient gel electrophoresis under non-
reducing and non-heat-denaturing conditions. This simple method
has been used for the separation and semi-quantiﬁcation of differ-
ent adiponectin oligomers [13,24,26,36]. The antibody, which is
raised against the globular domain of adiponectin, recognizes spe-
ciﬁcally the oligomeric forms of adiponectin [13]. When berberine
was present during differentiation, the levels of LMW, MMW and
HMW adiponectin were decreased. However, berberine preferen-
tially reduced the level of LMW adiponectin; LMW adiponectin
was not detected in the cells when 2 or 4 lM berberine was pres-
ent at day 6 or day 8 (Fig. 1C, top panel). The HMW/Total ratio is
increased three or ﬁvefold for day 6 or day 8, respectively. Based
on the fact that transcription of adiponectin and the total amount
of adiponectin are signiﬁcantly reduced by berberine (Fig. 1B and
C, middle panel), we hypothesize that berberine might promote
the assembly of LMW adiponectin into HMW adiponectin during
differentiation of 3T3-L1 preadipocytes.
3.2. Berberine promotes assembly of HMW adiponectin in adipocytes
To investigate the effect of berberine on adiponectin multimer-
ization in mature adipocytes, we treated fully differentiated 3T3-L1
cells with different concentrations of berberine for different length
of time. The level of adiponectin mRNA was reduced by berberine
(Fig. 2A). Western blot analysis of cell lysates from berberine-trea-
ted cells revealed a substantial decrease in the total amount of
adiponectin after treatment for 24 or 48 h (Fig. 2B). Therefore,
Fig. 1. Berberine promotes adiponectin multimerization during differentiation.
3T3-L1 preadipocytes were induced to differentiate in the presence of 0, 2, or 4 lM
berberine (BBR). (A) At day 8 post-differentiation, cells were stained with Oil Red O.
(B) Total RNA was isolated from cells after differentiation for 8 days. Expression of
adiponectin, aP2 and PPARc were examined by real-time PCR. Data are expressed
relative to b-actin. Values given are the mean ± S.D. (n = 3). ⁄P < 0.05; ⁄⁄P < 0.01. (C)
At days 4, 6, and 8 post-differentiation, cells were harvested and subjected to 2–15%
SDS–PAGE under non-reducing and non-heat-denaturing conditions. Three oligo-
meric forms of adiponectin (LMW, MMW and HMW) were detected by western blot
analysis using anti-globular domain antibodies (top panel). Cell lysates were also
subjected to SDS–PAGE after reduction and denaturation. The total amount of
adiponectin (Total Ad) or actin was detected with antibodies against adiponectin
(using anti-adiponectin N-terminal peptide antibody) (middle panel), or b-actin
(bottom panel). Results are representative of at least three independent experi-
ments with similar results.
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adipocytes. However, when we examined adiponectin oligomers in
the cell lysates, we found that the level of LMW adiponectin was
signiﬁcantly decreased after 24-h treatment, whereas the level of
HMW adiponectin was increased after 48-h treatment (Fig. 2B).
The decrease in LMW adiponectin and the increase in HMW adipo-
nectin were conﬁrmed by velocity sedimentation on sucrose gradi-
ents (Fig. 2C). The HMW/Total ratio is increased by berberine in a
dose-dependent and time-dependent way (Fig. 2D). Therefore, ber-
berine promotes adiponectin multimerization in adipocytes.
3.3. Knockdown of AMPKa1 abolishes the effect of berberine on
adiponectin multimerization
Berberine activates AMPK in 3T3-L1 adipocytes, increasing the
phosphorylation of AMPKa at Thr172 [28,31]. We also found that
the level of phosphorylated AMPK was increased after cells were
treated with berberine (Fig. 3A), suggesting that the AMPK path-
way might mediate the effect of berberine. To conﬁrm this, wesuppressed the expression of endogenous AMPKa1 using the siRNA
approach. Transfection of siRNA oligonucleotides targeting AMP-
Ka1 resulted in a substantial reduction of the corresponding pro-
tein (Fig. 3B). It is reported that activation of AMPK by berberine
increases phosphorylation of PPARc and inhibits its transcriptional
activity [31]. Knockdown of AMPKa1 abolishes the effect of berber-
ine on adiponectin multimerization and expression; the level of
adiponectin oligomers (LMW, MMW and HMW) and the total
amount of adiponectin remained unchanged after berberine treat-
ment in cells transfected with AMPKa1 siRNA (Fig. 3B). The HMW/
Total ratio is not increased by berberine when AMPKa1 expression
is suppressed (Fig. 3C). Berberine-mediated effect was not changed
by speciﬁc inhibitors, including PD98059 (ERK inhibitor), U0126
(inhibitor of MEK1/2), LY294002 (inhibitor of PI3K), or SP600125
(inhibitor of JNK) (data not shown). Taken together, these results
suggested that the AMPK signaling pathway is involved in berber-
ine-mediated promotion of adiponectin multimerization.
3.4. Activation of AMPK by AICAR promotes adiponectin
multimerization
To further conﬁrm that the AMPK signaling pathway is involved
in regulating adiponectin multimerization, we treated 3T3-L1 adi-
pocytes with AICAR, activator of AMPK. The level of phosphory-
lated AMPK was increased after treated with AICAR (Fig. 4A). We
found that the level of LMW adiponectin was decreased, but the le-
vel of HMW adiponectin was increased after treatment with AICAR
(Fig. 4B). The total amount of adiponectin was also decreased after
AICAR treatment (Fig. 4B), leading to an increased ratio of HMW to
total adiponectin (Fig. 4C). Treatment of 3T3-L1 adipocytes with
metformin, which also activates AMPK, shows the same effect on
adiponectin multimerization as berberine (data not shown). These
results further demonstrate that activation of AMPK promotes
adiponectin multimerization.4. Discussion
Despite the extensive research on the physiological functions of
adiponectin, little is known about the mechanisms that govern
adiponectin multimerization in the adipocytes. Here, we report
that berberine promotes adiponectin multimerization during dif-
ferentiation and in fully-differentiated 3T3-L1 adipocytes. The
AMPK signaling pathway is involved in the regulation; suppressing
AMPKa1 expression abolishes the effect of berberine, whereas acti-
vation of AMPK by AICAR also increases the level of HMW adipo-
nectin. Therefore, activation of AMPK promotes adiponectin
multimerization.
Activation of AMPK has been linked to a number of energy-con-
serving cellular processes [37]. AMPK activation is also central to
the metabolic effects of adiponectin [8,9,38,39]. In liver and mus-
cle, the insulin-sensitizing effect of adiponectin is mainly mediated
by activation of AMPK [8,9]. In adipocytes, activation of AMPK by
berberine and AICAR promotes the assembly of LMW adiponectin
into HMW adiponectin (this study). Our study reveals a novel reg-
ulatory role of AMPK in the biosynthesis of adiponectin, providing
more evidence that AMPK would be a prime therapeutic target for
obesity-related metabolic diseases.
AICAR and berberine have been reported as potent inhibitors of
adipogenesis [31,34,40]. Our results also demonstrate that berber-
ine inhibits differentiation of 3T3-L1 preadipocytes (Fig. 1A). The
inhibitory effect of berberine is the result of reduced PPARc activ-
ity, as expression of other PPARc target genes, such as aP2 and
DsbA-L, is also inhibited by berberine (Figs. 1B, 2A and B). There-
fore, activation of AMPK inhibits preadipocyte differentiation. In
addition, we show that activation of AMPK by either berberine or
Fig. 2. Berberine promotes assembly of HMW adiponectin in 3T3-L1 adipocytes. (A) Mature 3T3-L1 adipocytes were treated with 0, 4, or 8 lM berberine (BBR) for 48 h. Total
RNA was isolated and expression of adiponectin, aP2 and PPARc were examined as described in Fig. 1B. (B) 3T3-L1 adipocytes were treated with berberine for 6, 24 or 48 h.
Adiponectin oligomers and the total amount of adiponectin in the cell lysates were detected as described in Fig. 1C. DsbA-L was detected using anti-DsbA-L antibody. (C) Cell
lysates of BBR 0 and 8 lM of 48-h treatment were fractionated by velocity sedimentation on sucrose gradient. Gradient fractions of equal volumes were analyzed by western
blotting after reduction and denaturation. (D) The total amount of adiponectin or the relative abundance of each oligomer were quantiﬁcated by analyzing the blot shown in
Fig. 2B using the NIH ImageJ software and the HMW/Total ratio of adiponectin was calculated. The results are presented as the ratio of HMW/Total relative to control (BBR
0 lM) and as means ± S.D. (n = 3).
Fig. 3. Knockdown of AMPKa1 abolishes the effect of berberine on adiponectin multimerization. (A) 3T3-L1 adipocytes were treated with berberine for 1 h. Cell lysates were
subjected to SDS–PAGE and western blot analysis using antibodies speciﬁc for phospho-AMPK or AMPKa. (B) 3T3-L1 adipocytes were transfected with AMPKa1 siRNA or
control siRNA. 48 h after transfection, cells were treated with berberine for 48 h. Adiponectin oligomers and the total amount of adiponectin were detected as described in
Fig. 1C. AMPKa1 was detected using antibodies speciﬁc for AMPKa1. (C) The HMW/Total ratio was calculated and presented as described in Fig. 2D.
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Fig. 4. Activation of AMPK by AICAR promotes assembly of HMW adiponectin. (A)
3T3-L1 adipocytes were treated with AICAR (0 or 0.5 mM) for 1 h. Cell lysates were
subjected to western blot analysis using antibodies speciﬁc for phospho-AMPK or
AMPKa. (B) 3T3-L1 adipocytes were treated with AICAR for 48 h. Adiponectin
oligomers and the total amount of adiponectin were detected as described in
Fig. 1C. (C) The HMW/Total ratio was calculated and presented as described in
Fig. 2D.
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was seen when 3T3-L1 adipocytes were treated with berberine
plus AICAR (data not shown). Therefore, our study suggested that
the AMPK signaling pathway plays a dual role in regulating adipo-
nectin biosynthesis. On one hand, it inhibits the transcription of
adiponectin by inhibiting the transcriptional activity of PPARc,
resulting in reduced expression of adiponectin. On the other hand,
it promotes the assembly of LMW adiponectin into HMW adipo-
nectin, leading to an increased ratio of HMW to total adiponectin.
Our results with AMPKa1 siRNA support this model; both effects of
berberine on adiponectin were abolished when AMPKa1 expres-
sion was suppressed (Fig. 3B). This novel role of AMPK was further
demonstrated by our recent study in which we found that some
ingredients from traditional Chinese medicine also promote adipo-
nectin multimerization. All of these ingredients activate AMPK
(unpublished results).
Berberine has been demonstrated to have beneﬁcial effects in
type 2 diabetes through multipathway mechanism [41]. It lowers
blood glucose by increasing the expression of insulin receptor
and reduces serum cholesterol by stabilizing LDLR mRNA [30,32].
It has also been reported to activate glucose uptake and increase
insulin sensitivity [28,29]. Berberine activates AMPK indirectly by
inhibiting mitochondrial ATP production and altering cellular
AMP: ATP ratios [42]. We found that berberine also increases theHMW/Total ratio in the culture medium (data not shown). There-
fore, our results suggest another mechanism by which berberine
increases insulin sensitivity. By activating the AMPK signaling
pathway, berberine promotes the assembly of HMW adiponectin
and increases the HMW/Total ratio, which shows a strong correla-
tion with insulin sensitivity.
The composition of adiponectin oligomers in circulation, partic-
ularly the ratio of HMW to total adiponectin can be reversed by
pharmacological and lifestyle interventions. Replenishment of
adiponectin represents a novel strategy for the treatment of obes-
ity-related diseases. Given the fact that adiponectin mRNA is tran-
scribed at high levels in adipocytes, targeting the assembly
pathway would be an alternative approach to increase the HMW
adiponectin [21,36]. We found that the AMPK signaling pathway
plays a positive role in regulating the assembly of HMW adiponec-
tin. However, activation of AMPK leads to decreased expression of
DsbA-L (Figs. 2B and 4B). It is also the case for Ero1-La (data not
shown). Based on these results, we propose that the AMPK signal-
ing pathway might promote adiponectin multimerization indepen-
dent of Ero1-La and DsbA-L. Identiﬁcation and characterization of
proteins involved in AMPK-mediated regulation are currently
underway. Proteins that play critical roles in the multimerization
of adiponectin will have the potential to be developed for adipo-
nectin-targeted pharmacological therapies for obesity-related met-
abolic diseases [39]. Design or discover new AMPK activators with
fewer side effects would be another alternative to increase the le-
vel of HMW adiponectin in the adipocytes.
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